GE presents data on Flutemetamol PET imaging agent to detect amyloid
31 Jan 2011
New clinical research data suggests that [18F] Flutemetamol
could add value to current diagnostic tools used to provide accurate
identification of beta amyloid plaques in the brain.
The plaques are considered to be a sign of neurodegeneration linked
to Alzheimer's Disease (AD).
Flutemetamol, a GE Healthcare PET imaging agent currently in
phase III development, is being studied to identify the uptake of
beta amyloid via imaging of the brain tissue in live humans.
Currently, beta amyloid is identified from brain samples acquired
post-mortem. Together with other GE Healthcare imaging modalities,
this may help physicians detect amyloid deposition and assist in the
detection and treatment of AD.
"The wealth of data presented this year at the annual HAI meeting
fundamentally supports the value Flutemetamol could bring to the
Alzheimer's community," said Jonathan Allis, MI PET Segment Leader,
GE Healthcare Medical Diagnostics. "The ability to make visual
assessments of amyloid in AD patients may enable physicians to seek
earlier, confirmed diagnosis of AD and make more informed care
Data highlights from five clinical abstracts from studies of
Flutemetamol to be featured at the 5th Annual Human Amyloid Imaging
(HAI) meeting in Miami, Florida suggest that:
- the in vivo PET retention of Flutemetamol and PIB
(Pittsburgh Compound B) have comparable patterns of binding;
- there is a strong concordance between Flutemetamol amyloid
imaging and cortical biopsy histopathology using both visual and
- the combination of Flutemetamol and structural MRI can
provide information that could be useful in understanding other
(non-AD) neuro-degenerative diseases and in identifying beta
amyloid formation; and
- Flutemetamol scans can be categorized with automated
software suitable for use in clinical practice.
"At GE Healthcare, our scientists and researchers remain fully
committed to developing enhanced diagnostics tools that may help
Alzheimer's Disease patients and their families get accurate
information as early as possible," said Pascale Witz, CEO, GE
Healthcare Medical Diagnostics.